A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity
PG Conaghan - Rheumatology international, 2012 - Springer
Non-steroidal anti-inflammatory drugs (NSAIDs) represent a diverse class of drugs and are
among the most commonly used analgesics for arthritic pain worldwide, though long-term …
among the most commonly used analgesics for arthritic pain worldwide, though long-term …
[HTML][HTML] Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review
Objective Summarize the comparative effectiveness of oral non-steroidal anti-inflammatory
drugs (NSAIDs) and opioids in reducing knee osteoarthritis (OA) pain. Methods Two …
drugs (NSAIDs) and opioids in reducing knee osteoarthritis (OA) pain. Methods Two …
[HTML][HTML] Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib
MC Hochberg, J Martel-Pelletier, J Monfort… - Annals of the …, 2016 - ard.bmj.com
Objectives To compare the efficacy and safety of chondroitin sulfate plus glucosamine
hydrochloride (CS+ GH) versus celecoxib in patients with knee osteoarthritis and severe …
hydrochloride (CS+ GH) versus celecoxib in patients with knee osteoarthritis and severe …
Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from …
AD Sawitzke, H Shi, MF Finco, DD Dunlop… - Annals of the …, 2010 - ard.bmj.com
Background Knee osteoarthritis (OA) is a major cause of pain and functional limitation in
older adults, yet longer-term studies of medical treatment of OA are limited. Objective To …
older adults, yet longer-term studies of medical treatment of OA are limited. Objective To …
Non‐steroidal anti‐inflammatory drug‐induced cardiovascular adverse events: a meta‐analysis
BR Gunter, KA Butler, RL Wallace… - Journal of clinical …, 2017 - Wiley Online Library
What is known and objective Although non‐steroidal anti‐inflammatory drugs (NSAID s)
have been studied in randomized, controlled trials and meta‐analyses in an effort to …
have been studied in randomized, controlled trials and meta‐analyses in an effort to …
Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation
Context Authorship in biomedical publication provides recognition and establishes
accountability and responsibility. Recent litigation related to rofecoxib provided a unique …
accountability and responsibility. Recent litigation related to rofecoxib provided a unique …
Celecoxib for osteoarthritis
Background Osteoarthritis (OA) is the most common form of arthritis and is caused by
degeneration of the joint cartilage and growth of new bone, cartilage and connective tissue …
degeneration of the joint cartilage and growth of new bone, cartilage and connective tissue …
A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin®for treatment of osteoarthritis of the knee
K Sengupta, KV Alluri, AR Satish, S Mishra… - Arthritis research & …, 2008 - Springer
Introduction 5-Loxin® is a novel Boswellia serrata extract enriched with 30% 3-O-acetyl-11-
keto-beta-boswellic acid (AKBA), which exhibits potential anti-inflammatory properties by …
keto-beta-boswellic acid (AKBA), which exhibits potential anti-inflammatory properties by …
Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials
RR Bannuru, TE McAlindon, MC Sullivan… - Annals of internal …, 2015 - acpjournals.org
Background: Placebo controls are essential in evaluating the effectiveness of medical
treatments. Although it is unclear whether different placebo interventions for osteoarthritis …
treatments. Although it is unclear whether different placebo interventions for osteoarthritis …
Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis
PL McCormack - Drugs, 2011 - Springer
Celecoxib (Celebrex®) was the first cyclo-oxygenase (COX)-2 selective inhibitor (coxib) to
be introduced into clinical practice. Coxibs were developed to provide anti-inflammatory …
be introduced into clinical practice. Coxibs were developed to provide anti-inflammatory …